Moderna Reshuffles Leadership as Delaware Patent Ruling and Citi Downgrade Test Its Record Run

Moderna appoints Juan Andres as COO as Jerh Collins retires; Citigroup cuts shares to Sell, and a Delaware judge rejects a patent defense.

Moderna is drawing a new operational map for the next leg of its corporate life, naming Juan Andres to the freshly created post of Chief Operating Officer effective Monday. The appointment lands alongside the retirement of Jerh Collins, who has served as Chief Technical Operations and Quality Officer. The company confirmed both moves in an 8-K filing with the U.S. Securities and Exchange Commission and accompanying Regulation FD disclosures.

The reorganization is designed to steer growth and diversification as Moderna positions itself for a possible market launch and industrial scale-up of its intismeran autogene candidate. Andres returns to the business to run day-to-day operations through that ramp-up, a step that follows the clinical momentum around the INTerpath-001 study. Phase 3 data on the cancer vaccine, released roughly two weeks ago, had already given the stock a visible lift.

A Sell Rating Arrives After a 535% Climb

Not everyone is cheering. Citigroup cut its rating on the shares to Sell from Neutral on Wednesday, even as it raised its price target to $80 from $60. The analysts argued that the rally has outrun the fundamental valuation assumptions attached to the oncology pipeline. Media reports tied the downgrade to share price losses, though the stock remains up 535% since the start of the year.

The equity closed Friday's session at EUR 168.62, holding within 8.3% of its 52-week high of EUR 183.98. A further catalyst sits on the calendar: on October 9, Moderna will join the Nasdaq-100, taking the slot vacated by media group Warner Bros. Discovery.

Delaware Judge Strips Away a Key Defense

Legal risk has resurfaced as a parallel pressure point. A federal judge in Delaware rejected Moderna's central defense in its patent dispute with Northwestern University, declining to accept the argument that a U.S. government patent license shielded the company from infringement claims. Reuters reported the ruling.

The decision is not a final judgment on the merits. The court expressly left open whether Moderna actually infringed the university's patents. Even so, the ruling weakens the company's bargaining position in the ongoing case, and for investors such proceedings mainly mean persistent uncertainty over potential future licensing payments or damages.

The setback fits into a broader pattern of litigation. On September 28, the same Delaware judge denied motions by Moderna as well as rivals Pfizer and BioNTech to dismiss patent suits brought by Bayer CropScience. Those claims assert rights over portions of the mRNA technology used in COVID-19 vaccines during the pandemic. With the dismissal motions rejected, the vaccine makers must now answer the substantive allegations in court.